By Counterforce Health Team in Emgality (galcanezumab-gnlm) —

Aetna CVS Health's Coverage Criteria for Emgality (galcanezumab-gnlm) in New Jersey: What Counts as "Medically Necessary"?

Answer Box: Getting Emgality Approved by Aetna CVS Health in New Jersey

To get Emgality (galcanezumab-gnlm) covered by Aetna CVS Health in New Jersey, you must meet their step therapy requirement: documented failure, intolerance, or contraindication to at least two generic migraine preventives (typically topiramate and propranolol). Your doctor submits a prior authorization through CVS Caremark with clinical documentation. If denied, you have 60 days for internal appeals, then up to 180 days for New Jersey's external review through IHCAP/Maximus. Start today: gather records of previous migraine preventive trials and have your doctor submit the PA request via CVS Caremark's provider portal.

Table of Contents

  1. Policy Overview: How Aetna CVS Health Covers Emgality
  2. FDA Indication Requirements
  3. Step Therapy & Medical Exceptions
  4. Quantity and Frequency Limits
  5. Required Diagnostics and Documentation
  6. Specialty Pharmacy Requirements
  7. Evidence to Support Medical Necessity
  8. Sample Medical Necessity Narrative
  9. Edge Cases and Special Situations
  10. Appeals Process in New Jersey
  11. Common Denial Reasons & Solutions
  12. Quick Reference Checklist
  13. FAQ

Policy Overview: How Aetna CVS Health Covers Emgality

Aetna CVS Health classifies Emgality (galcanezumab-gnlm) as a specialty medication requiring prior authorization across all plan types—HMO, PPO, and Medicare Advantage. The drug is managed through CVS Caremark's specialty pharmacy network and typically placed on a high-tier formulary position.

Plan Types Coverage:

  • Commercial Plans: Step therapy required; 2+ generic preventive failures documented
  • Medicare Advantage: Similar criteria with additional age-related considerations
  • Medicaid (NJ FamilyCare): May have additional state-specific requirements

Find your specific plan's formulary and prior authorization criteria in your Aetna member portal or the official CVS Caremark formulary documents.

FDA Indication Requirements

Emgality has two FDA-approved indications that Aetna CVS Health covers:

  1. Migraine Prevention (adults): 240 mg loading dose, then 120 mg monthly
  2. Episodic Cluster Headache: 300 mg monthly during cluster periods

On-Label vs. Off-Label Considerations:

  • Coverage is primarily limited to FDA-approved uses
  • Off-label use requires additional clinical justification and peer-reviewed evidence
  • Diagnosis must be supported by ICD-10 codes: G43.x (migraine) or G44.0 (cluster headache)

Step Therapy & Medical Exceptions

Aetna CVS Health requires documented failure of at least two generic migraine preventives before approving Emgality. The most commonly required medications include:

Required Step Therapy Trials:

  • Topiramate (minimum 3-month trial at therapeutic dose)
  • Propranolol or other beta-blocker (minimum 3-month trial)

Alternative acceptable preventives may include:

  • Amitriptyline or nortriptyline
  • Valproic acid/divalproex
  • Verapamil (for cluster headache)

Medical Exception Pathways

You can bypass step therapy with documented:

  • Contraindications: Medical conditions preventing safe use
  • Drug interactions: With current medications
  • Previous intolerance: Documented adverse reactions
  • Clinical urgency: Severe, frequent migraines affecting daily function

Documentation Requirements:

  • Specific drug name, dose, duration of trial
  • Reason for discontinuation (ineffective, side effects, contraindication)
  • Clinical notes from treating physician
  • Pharmacy records showing prescription fills
Tip: Keep detailed records of all migraine preventive trials, including over-the-counter supplements, as some plans accept magnesium or riboflavin failures as part of step therapy documentation.

Quantity and Frequency Limits

Aetna CVS Health enforces strict quantity limits based on FDA-approved dosing:

Indication Initial Dose Maintenance Monthly Limit
Migraine Prevention 240 mg (2 x 120 mg pens) 120 mg monthly 2 pens first month, then 1
Episodic Cluster 300 mg (3 x 100 mg syringes) 300 mg monthly 3 syringes

Renewal Requirements:

  • Coverage typically approved for 6-12 months initially
  • Renewal requires documentation of clinical benefit
  • Frequency restrictions: No more than monthly dosing permitted

Required Diagnostics and Documentation

Essential Clinical Documentation:

  • Migraine diary showing frequency (typically ≥4 migraine days per month)
  • Neurological examination findings
  • Exclusion of secondary headache causes
  • Current medication list and allergy history

Timing Requirements:

  • Documentation must be current (within 6 months for most plans)
  • Step therapy trials should be recent (within 12-24 months)
  • Baseline migraine frequency established over 3-month period

Specialty Pharmacy Requirements

Emgality must be dispensed through CVS Specialty Pharmacy for most Aetna plans:

Routing Rules:

  • Cannot be filled at retail pharmacies
  • Must use designated specialty network
  • Prior authorization processed through CVS Caremark system

Infusion vs. Self-Administration:

  • Emgality is self-administered subcutaneous injection
  • No infusion center requirements
  • Patient education and injection training provided by specialty pharmacy

Evidence to Support Medical Necessity

Primary Evidence Sources:

Supporting Clinical Data:

  • Peer-reviewed efficacy studies showing reduction in monthly migraine days
  • Safety data for long-term use
  • Comparative effectiveness vs. other CGRP inhibitors

How to Cite in Appeals:

  • Reference specific sections of FDA label
  • Include PMID numbers for peer-reviewed studies
  • Cite relevant guideline recommendations with page numbers

Sample Medical Necessity Narrative

Clinician Corner: Medical Necessity Letter Template

"Patient is a [age]-year-old with chronic migraine (ICD-10: G43.709) experiencing [X] migraine days per month despite trials of topiramate 100mg daily for 4 months (discontinued due to cognitive side effects) and propranolol 80mg daily for 3 months (discontinued due to fatigue and inadequate efficacy). Current migraine frequency significantly impairs work productivity and quality of life. Emgality 240mg loading dose followed by 120mg monthly is requested per FDA-approved dosing for migraine prevention. Patient has no contraindications to CGRP inhibitors and understands injection technique. Clinical monitoring plan includes monthly follow-up for first 3 months, then quarterly assessments of migraine frequency and functional status."

Edge Cases and Special Situations

Pediatric Use:

  • Emgality not FDA-approved for patients under 18
  • Off-label pediatric use requires additional justification

Pregnancy Considerations:

  • Limited safety data in pregnancy
  • Risk-benefit analysis required for coverage during pregnancy

Comorbidity Considerations:

  • Cardiovascular disease history may support bypassing beta-blocker step therapy
  • Psychiatric conditions may contraindicate certain preventives

Escalation Paths:

  • Peer-to-peer review with Aetna medical director
  • External clinical consultation requests
  • State insurance commissioner complaint if coverage inappropriately denied

Appeals Process in New Jersey

If your Emgality prior authorization is denied, New Jersey offers robust appeal rights:

Internal Appeals (Aetna CVS Health):

  1. First-level appeal: 60 days to file, 30 days for decision
  2. Second-level appeal: 60 days to file, 30 business days for decision
  3. Expedited appeals: 72 hours for urgent medical situations

External Review (IHCAP): After exhausting internal appeals, you can request an independent external review through New Jersey's Independent Health Care Appeals Program (IHCAP), administered by Maximus Federal Services:

  • Filing deadline: 180 days from final internal denial
  • Filing fee: $25 (reduced to $2 for financial hardship)
  • Decision timeline: 45 days for standard review
  • Contact: 1-888-393-1062 for IHCAP assistance
From our advocates: We've seen many Emgality denials overturned at the external review level when the appeal included comprehensive documentation of step therapy failures and a detailed medical necessity letter. The key is ensuring all required prior preventive trials are clearly documented with specific reasons for discontinuation.

For help with the appeals process, contact the New Jersey Department of Banking and Insurance Consumer Hotline at 1-800-446-7467.

Common Denial Reasons & Solutions

Denial Reason Solution Required Documentation
Insufficient step therapy Provide detailed records of 2+ preventive failures Pharmacy records, clinical notes, specific doses/durations
Not medically necessary Submit comprehensive medical necessity letter Migraine diary, functional impact assessment, treatment goals
Non-formulary status Request formulary exception Comparative efficacy data, contraindications to preferred alternatives
Quantity limit exceeded Justify FDA-approved dosing Prescribing information, clinical rationale for specific dose
Experimental/investigational Provide FDA approval documentation FDA label, clinical practice guidelines

Counterforce Health helps patients and providers navigate these complex prior authorization requirements by analyzing denial letters and crafting targeted, evidence-based appeals. Our platform identifies the specific denial basis and generates point-by-point rebuttals aligned with each payer's own coverage criteria. Learn more about our appeal assistance services.

Quick Reference Checklist

Before Starting Your PA Request:

  • Migraine diagnosis confirmed with ICD-10 code
  • 3+ months of migraine diary documentation
  • Records of 2+ generic preventive medication trials
  • Current medication list and allergy history
  • Insurance card and member ID number

Required for Medical Necessity:

  • Specific failed preventives with doses, durations, reasons for discontinuation
  • Current migraine frequency and severity
  • Functional impact assessment
  • Treatment goals and monitoring plan
  • FDA prescribing information reference

Appeal Documentation:

  • Original denial letter
  • Complete medical records
  • Pharmacy records showing step therapy attempts
  • Medical necessity letter from prescriber
  • Supporting clinical literature

FAQ

How long does Aetna CVS Health prior authorization take in New Jersey? Standard PA decisions are made within 5-15 business days. Expedited requests for urgent medical situations are processed within 72 hours.

What if Emgality is not on my formulary? You can request a formulary exception by demonstrating medical necessity and providing evidence that preferred alternatives are inappropriate or ineffective.

Can I request an expedited appeal? Yes, if delays in treatment could seriously jeopardize your health. Your doctor must provide clinical justification for the urgency.

Does step therapy apply if I failed preventives outside New Jersey? Yes, documented failures from other states are typically accepted if you have complete medical records showing the trials.

What's the cost if my appeal is denied? The New Jersey external review process costs only $25 ($2 with financial hardship documentation). There are no additional fees for internal appeals.

Can my doctor request a peer-to-peer review? Yes, providers can request to speak directly with an Aetna medical director to discuss the clinical rationale for Emgality coverage.

Counterforce Health specializes in turning insurance denials into successful appeals by analyzing payer-specific coverage criteria and generating evidence-backed rebuttals. Our platform helps patients, clinicians, and specialty pharmacies navigate complex prior authorization requirements for medications like Emgality. Visit our website to learn how we can help streamline your coverage approval process.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance plan for specific coverage decisions. Coverage criteria and appeal processes may vary by plan and can change. Verify current requirements with your insurer and state insurance department.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.